secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008314
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa reports preliminary cash balance of ~$40M, limited other details
-----------------------------------------------------------------------

- Estimated cash and cash equivalents of ~$40M as of Dec 31, 2025, preliminary and unaudited.
- No quarterly earnings, revenue, or operational results were disclosed in this filing.
- Updated corporate presentation likely focuses on (Z)-Endoxifen development strategy per forward-looking statements.
- Cash estimate subject to finalization of year-end financial closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/0001193125-26-008314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/atos-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer